Filing Flows › Emmaus Life Sciences (EMMA) › Q4 2025
Emmaus Life Sciences (EMMA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 31, 2026
Emmaus Life Sciences (EMMA) reported revenue of $3.9M for the fourth quarter 2025 (Q4 2025), +17% from a year earlier and +14% from the quarter before. Operating margin was 23.0%, net loss $2.0M (50.6% of revenue).
Emmaus Life Sciences, Q4 2025: revenue $3.9M (+17% year over year), operating margin 23.0%, net loss $2.0M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.9M | +14% | +17% |
| Operating profit | $886K | +27% | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | $2.2M | +440% | +544% |
What changed
Revenue was $3.9M in Q4 2025, up 17% year over year and up 14% from the previous quarter.
Gross margin was 93.9%, up 3.3 points from Q4 2024. Operating profit was $886K, a 23.0% margin (up 39.9 points year over year). Operating expenses fell 23% while revenue rose 17%. The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $2.1M loss. Net interest and other expense of $2.8M was the main reason.
Operating cash flow was $2.2M (up 544% year over year). Non-cash charges added back $15K of depreciation and $7K of share-based compensation. Working capital and other items added $4.1M.
Questions
What was Emmaus Life Sciences' revenue in the fourth quarter 2025?
Emmaus Life Sciences (EMMA) reported revenue of $3.9M for the fourth quarter 2025 (Q4 2025), +17% from a year earlier and +14% from the quarter before.
Was Emmaus Life Sciences profitable in the fourth quarter 2025?
Operating profit was $886K (23.0% of revenue) and net loss $2.0M.